Abstract: Activating neurotrophic tyrosine receptor kinase (NTRK) fusions, typically detected using nucleic-acid based assays, are highly targetable and define certain tumors. Here, we explore the utility of pan-TRK immunohistochemistry (IHC) to detect NTRK fusions. NTRK rearrangements were detected prospectively using MSK-IMPACT, a DNA-based next-generation sequencing assay. Transcription of novel NTRK rearrangements into potentially functional fusion transcripts was assessed via Archer Dx fusion assay. Pan-Trk IHC testing with mAb EPR17341 was performed on all NTRK rearranged cases and 20 cases negative for NTRK fusions on Archer. Of 23 cases with NTRK rearrangements, 15 had known activating fusions. Archer detected fusion transcripts in 6 of 8 novel NTRK rearrangements of uncertain functional significance. Pan-Trk IHC was positive in 20 of 21 cases with NTRK fusion transcripts confirmed by Archer. The discordant negative case was a mismatch repair-deficient colorectal carcinoma with an ETV6-NTRK3 fusion. All 20 additional Archer-negative cases had concordant pan-TRK IHC results. Pan-Trk IHC sensitivity and specificity for transcribed NTRK fusions was 95.2% and 100%, respectively. All positive IHC cases had cytoplasmic staining while the following fusion partner-specific patterns were discovered: all 5 LMNA-NTRK1 fusions displayed nuclear membrane accentuation, all 4 TPM3/4 fusions displayed cellular membrane accentuation, and half (3/6) of ETV6-NTRK3 fusions displayed nuclear staining. Pan-Trk IHC is a time-efficient and tissue-efficient screen for NTRK fusions, particularly in drivernegative advanced malignancies and potential cases of secretory carcinoma and congenital fibrosarcoma. Pan-Trk IHC can help determine whether translation occurs for novel NTRK rearrangements.
N eurotrophic tyrosine kinase receptor (NTRK) is a family of 3 proto-oncogenes including NTRK1, NTRK2, and NTRK3 which encode Trk A, Trk B, and Trk C proteins, respectively. The latter are involved in biological processes such as neuronal survival, differentiation, and plasticity under physiological circumstances. In various cancers, oncogenic fusions involving the kinase domain of NTRK1, NTRK2, or NTRK3 are present. Recently, detecting NTRK fusions has become increasingly important as Trk inhibitors have demonstrated a high response rate for patients with NTRK fusions. [1] [2] [3] [4] [5] [6] Screening NTRK fusions is usually done on a molecular level and can be achieved with next-generation sequencing (NGS) of DNA, or targeted RNA testing. However, molecular analyses are still expensive, comparable time-consuming and sampling error or nucleic acid degradation can pose a technical risk. Immunohistochemistry (IHC) is a well established method, usually less expensive and fast compared with current molecular tests. Here, we investigate pan-Trk IHC as a faster and more tissue-efficient method to identify NTRK fusions.
METHODS

Case Selection and NGS Screening
After approval by our institutional review board, all patients with solid cancers with NTRK1, NTRK2 or NTRK3 rearrangements detected by MSK-IMPACT were included for further RNA/IHC evaluation. MSK-IMPACT is a hybridization-based NGS assay which interrogates all exons and select introns and promoters of 410 genes (including NTRK1, NTRK2, and NTRK3) for the detection of fusions, mutations, and copy number alterations in formalin-fixed paraffin-embedded tumor tissue against matched normal blood. Both MSK-IMPACT and Archer are clinically validated and performed in a CLIA approved laboratory. Probes for introns 3, and 7 to 12 of NTRK1, and intron 15 of NTRK2 are included in MSK-IMPACT to detect rearrangements involving these 2 genes. In addition, probes for ETV6 introns 4 and 5 are included to detect ETV6-NTRK3 rearrangements. Other introns affected by NTRK rearrangements could not be included because they are too large for a DNA-based capture approach (approximate upper limit: 25 kb). (codons G12, G13, Q61, K117, A146) , and BRAF (codon G466, G469, V600), which are readily detect via MSK-IMPACT, were recorded.
Downstream hotspot mutations in KRAS/NRAS
Archer RNA Testing
NTRK-rearranged cases with available material were sent for RNA-based tested with Archer to assess specific novel NTRK1, NTRK2, and NTRK3 rearrangements for the production of NTRK fusion transcripts.
Pan-Trk IHC
IHC staining for Trk A, B, and C expression was performed with pan-Trk monoclonal antibody (mAb) clone EPR17341 (Abcam, Cambridge, MA). The antibody is reactive to a homologous region of Trk-A, Trk-B, and Trk-C near the C terminus, and the exact sequence is proprietary. This commercial antibody is not FDA approved for clinical use to our best knowledge. Testis tissue, ganglia of the colonic plexus submucosus and cortical brain tissue were used as positive control tissues. EPR17341 was used at 6 mg/mL. All assays were performed on a Leica-Bond-3 (Leica, Buffalo Grove, IL) automated stainer platform using a heat-based antigen retrieval method and high pH buffer solution (ER2, Leica). Non-neoplastic lymphocytes, hepatocytes, colorectal epithelium, alveolar epithelium, and renal cortex were used as negative external controls. All available cases with NTRK rearrangements on MSK-IMPACT as well as 20 consecutive tumors without evidence of NTRK fusion on Archer were stained.
RESULTS
MSK-IMPACT and Archer Results
A total of 23 cases with NTRK rearrangements detected on MSK-IMPACT and sufficient material for IHC were identified. Fifteen NTRK rearrangements were previously described in the literature while 8 were novel. Of these cases, Archer RNA testing was performed and positive for a fusion transcript in 10 of 15 cases with known Archer fusion (5 cases of known NTRK fusion detected by MSK-IMPACT were not tested via Archer) and 6 of 8 novel NTRK rearrangements while 2 of 7 novel NTRK rearrangements did not produce a fusion transcript.
The fusion cohort consisted of 5 colorectal carcinomas (2 LMNA-NTRK1 fusions, 2 TPM3-NTRK1 fusions, and 1 ETV6-NTRK3 fusion), 4 mammary analog secretory carcinomas (MASCs)/secretory carcinoma of salivary gland with ETV6-NTRK3 fusions, 3 glioblastomas (1 EML4-NTRK3 fusion, 1 novel AFAP1-NTRK3 fusion, and 1 novel BCR-NTRK2 fusion), 2 lung adenocarcinomas (1 IRF2BP2-NTRK1 fusion and 1 TPM3-NTRK1 fusion), 2 sarcomas (1 novel TPM4-NTRK3 fusion and 1 LMNA-NTRK1 fusion), 2 melanomas (1 novel TRIM63-NTRK1 fusion and 1 novel TRAF2-NTRK2 fusion), 1 gallbladder carcinoma with an LMNA-NTRK1 fusion, 1 secretory carcinoma of breast with an ETV6-NTRK3 fusion, and 1 appendiceal carcinoma with an LMNA-NTRK1 fusion. All above listed cases with NTRK fusions were negative for hotspot mutations in KRAS, NRAS, BRAF (see the Methods section) as well as negative for other (non-NTRK) activating fusions (via Archer testing). Two additional cases with NTRK rearrangements were also identified via MSK-IMPACT and were negative for fusion transcripts on Archer: a lung adenocarcinoma with an NTRK1 exon 5-P2RY8 exon 2 rearrangement, and a glioblastoma with an NTRK3 exon 14-ZNF710 exon 1 rearrangement (Table 1) .
Comparison of Pan-Trk In Situ Protein Expression Versus Molecular Analysis
Immunohistochemical analysis of Pan-Trk IHC was concordant with Archer RNA testing in 21 of 22 cases. Positive immunostaining was seen in 15 of 16 cases with known NTRK fusions and 5 novel NTRK rearrangements, which were positive for fusion transcripts. Two cases with NTRK rearrangements and negative Archer fusion testing results were also negative by IHC. There was only one discordant case of a fusion-positive colorectal carcinoma with a ETV6-NTRK3 fusion, which did not show any immunostaining with mAb EPR17341. An additional 20 consecutive cases of various tumors without NTRK fusions (NTRK fusion negative confirmed by Archer), were also negative by IHC for EPR17341. These negative cases included 11 lung adenocarcinomas, 2 uterine leiomyosarcomas, 1 osteosarcoma, 1 low-grade fibromyxoid sarcoma, 1 melanoma, 1 inflammatory myofibroblastic tumor, 1 intrahepatic cholangiocarcinoma, 1 alveolar soft part sarcoma, and 1 synovial sarcoma. These findings yielded a sensitivity of 95.2%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 96%.
There was no immunostaining present in nonneoplastic lymphocytes, hepatocytes, colorectal epithelium, alveolar epithelium, and renal cortex while testes tissue (which does express Trk when wild type) served as a positive external control.
Pan-Trk Staining Patterns
MAb EPR17341 displayed cytoplasmic labeling in all immunohistochemical positive cases. In addition to cytoplasmic immunoreactivity, staining patterns associated with specific NTRK fusion partners were observed. Three of 6 (50%) ETV6-NTRK3 fusions cases and the single case of EML4-NTRK3 had nuclear staining (Fig. 1) . All 5 LMNA-NTRK1 fusion cases showed staining of the nuclear membrane (Fig. 2) . All 4 TPM3/4-NTRK1/3 fusions and the single case of TRAF2-NTRK2 displayed membranous immunostaining of most tumor cells (Fig. 3) .
DISCUSSION
In the present study, we analyzed various types of molecularly pretyped cases of NTRK1-3 fusions by IHC using a reagent reactive with Trk-A, Trk-B, and Trk-C. Although NTRK fusions are collectively becoming more frequently identified, they remain rare in each individual cancer type (with the exception of very specific entities such as secretory carcinoma of salivary gland/MASC, secretory carcinoma of breast, and congenital fibrosarcoma). Our cohort represents one of the largest studies of NTRK fusion-positive cancers assembled to date. We show that NTRK fusions occur largely in mutual exclusivity of the most common driver mutations in KRAS, NRAS, and BRAF; and that IHC with mAb EPR17341 detects approximately 95% of positive cases and is 100% specific for NTRK fusions. Further, we demonstrate that staining pattern is indicative for some of the most common NTRK fusion partners: LMNA1, TPM3/4, and ETV6). This high specificity reflects the very restricted expression of native NTRK proteins in adult tissues, namely in as smooth muscles, testes, and neural components. [7] [8] [9] Indeed, in these tissues, the physiological expression of wild type NTRK proteins limits the usefulness of the IHC assay.
The current widely used methods used to detect NTRK fusions include DNA-based NGS, targeted panels using RNA, and fluorescence in situ hybridization. All 3 methods have advantages and drawbacks: while DNA-based NGS can precisely characterize some fusions as well as give information about other genomic events, the turnaround time can be several weeks and fusions may be missed due to difficulty tiling entire introns (either because of their size or because of the presence of repetitive regions); RNA-based targeted panels can precisely characterize fusion transcripts yet have turnaround time of at least a week and depend on the availability of sufficient RNA of adequate quality. Fluorescence in situ hybridization detection is comparably fast but does not answer the question of whether a specific rearrangement results in a transcribed (oncogenic) fusion or which partner gene is involved. Immunohistochemical analysis for Trk confers several benefits such as quick turnaround time, limited material required, only transcribed and translated fusions are detected rather than all DNA-level rearrangements, high sensitivity and specificity, and lower cost than other methods. Furthermore, IHC allows for a spatial assessment of the potential presence of the fusion protein. This may have implications for therapeutic approaches such as immunotherapy in which extent of antigen presence may be an important factor. Importantly, specific staining patterns appear to correlate with the subcellular localization of the fusion partners. Tumors with NTRK1-LMNA fusions showed a pronounced immunostaining at the nuclear membrane. This is congruent with the biology of LMNA, which encodes lamin A/C, a structural component of the inner nuclear membrane. Cases with TPM3/4 fusions displayed immunostaining of the tumor cell membrane. TPM3 and TPM4 both encode tropomyosins that form part of the cytoskeleton in nonmuscle cells and were shown to localize to the cell membrane in breast cancer. 10 The protein encoded by TRAF2 localizes to the cellular membrane as did pan-Trk IHC in the melanoma with the TRAF2-NTRK2 fusion. 11 Half of the present cases with ETV6-NTRK3 fusions had nuclear staining. ETV6 encodes a transcription factor, which localizes to the nucleus. Similar staining patterns have been reported for several of these genes when fused to other kinases. For instance, TPM3-ALK also shows membranous and nuclear staining, EML4-ALK shows cytoplasmic staining, CD30-ALCL shows staining of nucleoli and course granular cytoplasmic staining. [12] [13] [14] While overall sensitivity in this cohort was 95%, there was a colorectal carcinoma with an ETV6-NTRK3 fusion that was negative for pan-Trk IHC. This case was a mismatch repair-deficient colorectal carcinoma with a high mutation load and no other driver mutations. It is not known why this case was discordant, however, it is possible that high mutation load due to mismatch repairdeficiency resulted in mutations within the epitope recognized by the pan-TRK antibody.
The utility of pan-Trk IHC is triple: (1) rapid assessment of driver negative advanced malignancies which may harbor possible NTRK fusions to test patients for eligibility for targeted therapy with novel pan-Trk inhibitors, (2) assessment of translation as a surrogate for functionality for novel NTRK rearrangements detected via NGS, and (3) a method to confirm surgical pathology diagnoses in select tumors that are characterized by NTRK fusions such as secretory carcinoma of breast, secretory carcinoma of salivary gland/MASC, and congenital fibrosarcoma. [15] [16] [17] In summary, pan-TRK IHC is a sensitive, specific, and resource-efficient methodology to identify and/or confirm the presence of NTRK1-3 fusions. It may also assist in detecting the fusion partner based on staining pattern. Pan-Trk IHC may serve as an adjunct or alternative to nucleic acid testing for the assessment of NTRK fusions.
